In T2DM receiving exenatide alone, HbA1c reductions were not greater with eGFR ≥90 than ≥60 to <90.
In plain wordsIn diabetes patients receiving exenatide alone, higher kidney filtration did not produce greater blood sugar reductions.
- Peptide
- Exenatide (exendin-4)
- Outcome
- No significant changeExenatide HbA1c reduction by eGFR
- Study
n: not reported in source
- Comparator
- eGFR ≥60 to <90 mL/min/1.73 m²
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 28 weeksAs given in this study (human).
Measurements
- HbA1c reduction
- −17.7 mmol/mol
- exenatide QW, eGFR ≥90
- HbA1c reduction
- −16.9 mmol/mol
- exenatide QW, eGFR ≥60 to <90
- HbA1c reduction
- −1.62%
- exenatide QW, eGFR ≥90
- HbA1c reduction
- −1.55%
- exenatide QW, eGFR ≥60 to <90
Source sentences
In the exenatide once weekly plus dapagliflozin and dapagliflozin groups, but not the exenatide once weekly group, HbA1c reductions were greater among patients with eGFR ≥90 vs ≥60 to 2
1 context sentence(design, population, supporting numbers)
(least-squares mean reductions of -23.6 vs -19.0 mmol/mol [-2.16% vs -1.74%], -17.3 vs -12.0 mmol/mol [-1.58% vs -1.10%], and -17.7 vs -16.9 mmol/mol [-1.62% vs -1.55%] for the respective treatments)